Clinical Trials on Psoriasis Vulgaris in Japan

Total 125 results

Kyowa Kirin Co., Ltd.

Completed

A Phase 4 Clinical Study of Brodalumab

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Pfizer

Completed

Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)

Psoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK 4827

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
LEO Pharma

Completed

The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma
CMIC Co, Ltd. Japan

Completed

LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis

Psoriasis Vulgaris

Japan
Novartis Pharmaceuticals

Active, not recruiting

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Psoriasis Vulgaris | Pustular Psoriasis | Psoriatic Arthritis

Japan
LEO Pharma

Completed

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
Boehringer Ingelheim

Recruiting

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Generalized Pustular Psoriasis

Japan
Bristol-Myers Squibb

Recruiting

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) (RePhlect)

Plaque Psoriasis

Japan
Amgen

Completed

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

Psoriasis | Psoriatic Arthritis | Psoriasis Arthropatica

Japan
GlaxoSmithKline

Completed

Japanese Phase 1 Study of GSK2585823 (JPN P1)

Acne Vulgaris

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris

Acne Vulgaris

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
Coherus Biosciences, Inc.
Shire; Daiichi Sankyo Co., Ltd.

Completed

A Long Term Safety Extension Study (CHS-0214-05)

Rheumatoid Arthritis | Plaque Psoriasis

Japan
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Pfizer

Completed

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Kochi University

Completed

STA-21 Topical Efficacy on Psoriasis

Psoriasis

Japan
GlaxoSmithKline

Completed

Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects

Acne Vulgaris

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis

Psoriasis

Japan
LEO Pharma
Quintiles, Inc.

Completed

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Psoriasis

Japan
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
GlaxoSmithKline

Completed

Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

Acne Vulgaris

Japan
Bristol-Myers Squibb

Recruiting

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK4827

Psoriasis

Japan
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active Psoriatic Arthritis

United States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Psoriasis

Japan
Boehringer Ingelheim

Completed

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Generalized Pustular Psoriasis

Japan
Galderma R&D

Completed

Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.

Acne Vulgaris

Japan
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
GlaxoSmithKline

Completed

DUAC® Early Onset Efficacy Study in Japanese Subjects

Acne Vulgaris

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Psoriasis

Japan
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Sun Pharmaceutical Industries Limited

Recruiting

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

United States, Australia, Estonia, Japan, Poland, Slovakia, Spain, Taiwan, Czechia, Germany, Korea, Republic of, Italy
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (PENGUIN 1)

Psoriatic Arthritis

Korea, Republic of, United States, Taiwan, Australia, Canada, Japan, Poland, Spain, New Zealand, Czechia, Hungary, Bulgaria, Russian Federation
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE COMPLETE)

Psoriatic Arthritis

United States, Australia, Canada, Czechia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

Psoriasis

Japan
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom

3

Subscribe